| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
1138 |
| issn |
1746-045X
1746-0441 |
| issueIdentifier |
11 |
| pageRange |
1127-1138 |
| publicationName |
Expert Opinion on Drug Discovery |
| startingPage |
1127 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e57a2df28cd3d691c9ebea9a73b49d7b
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_916de93fe8f49855f42e16db43537393 |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_0a2256015fb9a9f8ab691264e35fae01
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_103fdb9285b0b21a64f9c8ed23ca7ae4
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3d826ab49e31e961071a7c30024ca9ed
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ce45b02071c29cd651c0ab1d93f735e2
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5a205e9b531b7f8949e20feb5c9674cd |
| bibliographicCitation |
Glicksman MA. The preclinical discovery of amyotrophic lateral sclerosis drugs. Expert Opinion on Drug Discovery. 2011 Oct 25;6(11):1127–38. doi: 10.1517/17460441.2011.628654. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_568185dcb81c4b914a094bd7bbab40f4 |
| date |
2011-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/PMC3367799
https://pubmed.ncbi.nlm.nih.gov/22646982
https://doi.org/10.1517/17460441.2011.628654 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1746-045X
https://portal.issn.org/resource/ISSN/1746-0441
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/36030 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
The preclinical discovery of amyotrophic lateral sclerosis drugs |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5070
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6865 |